ClinicalTrials.gg
RecruitingNCT06332170Updated Jul 18, 2024

ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors

A Phase 1 interventional study of HS-20093 and Adebrelimab in Advanced Solid Tumor, sponsored by Hansoh BioMedical R&D Company. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-18.

Sponsored by Hansoh BioMedical R&D Company (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
610
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of HS-20093 in combination with other anti-cancer agents in patients with advanced solid tumor patients.

Read the detailed description

This is a phase 1, open-label, multi-center, dose-escalation and expansion, phase 1 study in Chinses subjects with advanced solid tumors. This study is in design allowing assessment of safety, tolerability, pharmacokinetics and anti-tumor activity of HS-20093 in combination with other anti-cancer agents.

A total of 5 combination-treatments will be carried out in 3 cohorts. The target population of dose escalation part is patients have progressed on or intolerant to available standard therapies, and the dose expansion part will enroll patients who have not received prior treatment for advanced/metastatic disease.

All patients will be carefully followed for adverse events during the study treatment and for 90 days after the last dose of study drug. Subjects will be permitted to continue therapy with assessments for progression if the product is well tolerated and sustained clinical benefit exists.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Hansoh BioMedical R&D Company is the lead sponsor of 48 studies on the registry; 43 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least age of 18 years at screening;
  • or cytologically confirmed, locally advanced or solid tumors

    1. Dose escalation part will enroll advanced solid tumor for which standard treatment has proven ineffective or unavailable or intolerable.
    2. Dose expansion part will enroll patients who have not received prior treatment for advanced/metastatic disease.
  • least one extra-cranial according to 1
  • Agree to provide fresh or
  • (ECOG) Performance Status of 0\~1
  • >= 12 weeks
  • Agree to use medically accepted methods of
  • Men or women should be using adequate contraceptive measures throughout the study;
  • Females subjects must not be pregnant at screening or have evidence of non-
  • Signed and dated Form

Exclusion criteria

Exclusion Criteria:

  • Any of the following would exclude the subject from participation in the study:

treatment with any of the following: Previous or current treatment with B7-H3 targeted therapy Intolerable for any inhibitor, cetuximab, enzalutamide and cisplatin/ carboplatin Cytotoxic chemotherapy, agents and anticancer drugs within 14 days prior to the first scheduled dose of HS-20093 Prior treatment with a monoclonal antibody within 28 days prior to the first scheduled dose of HS-20093 Radiotherapy with a limited field of radiation for palliation within 2 weeks, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks prior to the first scheduled dose of HS-20093 Major surgery within 4 weeks prior to the first scheduled dose of HS-20093

  • Subjects with previous or concurrent
  • Inadequate bone marrow reserve or organ dysfunction
  • Evidence of cardiovascular risk
  • Evidence of current severe or uncontrolled systemic diseases
  • Evidence of mucosal or internal bleeding within 1 month prior to the first scheduled dose of HS-20093
  • Known active infection requiring antibodies treatment within 2 weeks, or severe infection within 4 weeks prior to the first scheduled dose of HS-20093
  • Subjects with current infectious diseases
  • History of neuropathy or mental disorders
  • Pregnant or lactating female
  • History of severe reaction, severe infusion reaction or idiosyncrasy to drugs chemically related to HS-20093 or any of the components of HS-20093
  • Unlikely to comply with study procedures, restrictions, and requirements in the opinion of the investigator
  • Any disease or condition that, in the opinion of the investigator, would compromise subject safety or interfere with study assessments
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
610 participants (estimated)

Study arms

  • Experimental
    Cohort 1a

    HS-20093 and Adebrelimab

    Drug: HS-20093 · Drug: Adebrelimab

  • Experimental
    Cohort 1b

    HS-20093, Adebrelimab and Cisplatin/ Carboplatin

    Drug: HS-20093 · Drug: Adebrelimab · Drug: Cisplatin/ Carboplatin

  • Experimental
    Cohort 2a

    HS-20093 and Cetuximab

    Drug: HS-20093 · Drug: Cetuximab

  • Experimental
    Cohort 2b

    HS-20093, Cetuximab and Cisplatin/ Carboplatin

    Drug: HS-20093 · Drug: Cisplatin/ Carboplatin · Drug: Cetuximab

  • Experimental
    Cohort 3a

    HS-20093 and Enzalutamide

    Drug: HS-20093 · Drug: Enzalutamide

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD) for combination-treatments

    To determine the MTD for further evaluation of HS-20093 with other anti-cancer agents in subjects with advanced solid tumors

    Time frame: Up to day 21 from the first dose

Secondary outcomes

  1. Incidence and severity of adverse events (AEs)

    AE assessed by investigator exclusively related to subject's underlying disease or medical condition \[graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0\]. Any untoward medical occurrence in a clinical study participant, whether or not considered related to the medicinal product. Incidence and severity of AEs are assessed according to vital signs, laboratory variables, physical examination, electrocardiogram, etc.

    Time frame: From the first dose through 90 days post end of treatment

  2. Objective response rate (ORR) determined by investigators

    Objective tumor response for target lesions will be assessed by imaging/measurement compared with the overall tumor burden at baseline. ORR is evaluated by the number of participants with best overall response of CR and PR (Confirmed CR/PR assessment require at least 1 repeat). For prostate cancer patients, ORR is determined by investigators according to RECIST 1.1 and Prostate Cancer Working Group 3 (PCWG3).

    Time frame: From the first dose up to PD or withdrawal from study, whichever came first, assessed up to 24 months

  3. Disease control rate (DCR) determined by investigators

    Objective tumor response for target lesions will be assessed by imaging/measurement compared with the overall tumor burden at baseline. DCR was evaluated by the number of participants with best overall response of CR, PR and stable disease (SD) \[Confirmed CR/PR assessment require at least one repeat (≥4 weeks); SD shall be assessed at least 5 weeks after the first dose\]. For prostate cancer patients, DCR is determined by investigators according to RECIST 1.1 and Prostate Cancer Working Group 3 (PCWG3).

    Time frame: From the first dose up to PD or withdrawal from study, whichever came first, assessed up to 24 months

  4. Duration of response (DoR) determined by investigators

    DoR was defined as the period from the first occurrence of CR or PR to PD or death from any cause. If no PD or death after CR/PR, the cut-off date of progression-free survival (PFS) would be used \[Confirmed CR/PR assessment require at least one repeat (≥4 weeks)\]. For prostate cancer patients, DoR is determined by investigators according to RECIST 1.1 and Prostate Cancer Working Group 3 (PCWG3).

    Time frame: From the first dose up to PD or death, whichever came first, assessed up to 24 months

  5. Progression-free survival (PFS) determined by investigators according to RECIST 1.1

    PFS was defined as the time from random assignment or first dose to PD or death from any cause.

    Time frame: From the first dose up to PD or death, whichever came first, assessed up to 24 months

  6. Overall survival (OS)

    OS was defined as the time from random assignment or first dose to death from any cause.

    Time frame: From the first dose up to death, whichever came first, assessed up to 24 months

  7. Radiographic progression-free survival (rPFS) determined by investigators according to RECIST 1.1 and PCWG3

    For prostate cancer patients, the rPFS is defined as the time from random assignment or first dose to the date of first documented PD per PCWG3 or death from any cause, whichever occurs first.

    Time frame: From the first dose up to PD or death from study, whichever came first, assessed up to 24 months

  8. Time to PSA progression (TTPP)

    In participants with a decrease in PSA from baseline: ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir value, which is confirmed by a consecutive second value obtained ≥ 3 weeks later. In participants with no decrease in PSA from baseline: ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the baseline value after 12 weeks.

    Time frame: From the first dose up to PD or withdrawal from study, whichever came first, assessed up to 24 months

  9. Prostate-specific cancer antigen (PSA) response rate

    PSA response is defined as a ≥ 50% decline in PSA from baseline with PSA confirmation ≥ 3 weeks after the first documented reduction in PSA of ≥ 50%.

    Time frame: From the first dose up to PD or withdrawal from study, whichever came first, assessed up to 24 months

  10. Time to first subsequent therapy (TFST)

    TFST was defined as the time from random assignment or first dose to the imitation of subsequent therapy or death.

    Time frame: From the first dose up to the imitation of subsequent therapy or death, whichever came first, assessed up to 24 months

  11. Observed maximum plasma concentration (Cmax) of HS-20093advanced solid tumor

    Cmax will be obtained after administration of the first dose of HS-20093

    Time frame: From pre-dose to study completion, assessed up to 24 months

  12. Time to reach maximum plasma concentration (Tmax) of HS-20093

    Tmax will be obtained after administration of the first dose of HS-20093

    Time frame: From pre-dose to study completion, assessed up to 24 months

  13. Terminal half-life (T1/2) of HS-20093 following the first dose

    T1/2 will be obtained after administration of the first dose of HS-20093

    Time frame: From pre-dose to study completion, assessed up to 24 months

  14. Area under plasma concentration versus time curve from zero to last sampling time (AUC0-t) following the first dose of HS-20093

    Area under the plasma concentration versus time curve from time zero to the last sampling time when the concentration was no less than the lower limit of quantification (LLQ). AUC0-t was calculated according to the mixed log-linear trapezoidal rule.

    Time frame: From pre-dose to study completion, assessed up to 24 months

  15. Percentage of participants with antibodies to HS-20093 in serum

    Serum samples were collected for the determination of anti-drug antibody (ADA) at designated time points.

    Time frame: From pre-dose to study completion, assessed up to 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for May 2026, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2024
First posted
Mar 27, 2024
StartActual
Apr 26, 2024
Primary completionEst.
May 30, 2026
CompletionEst.
May 30, 2028
Last update
Jul 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06332170
Responsible party
Sponsor
First posted
Mar 27, 2024
Start date
Apr 26, 2024
Primary completion
May 30, 2026 (estimated)
Completion
May 30, 2028 (estimated)
Last update
Jul 18, 2024

Study contacts

Hua Zhong, PhD
Contact
shsxkyy@hotmail.com
(0086)021-22200000

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risvutatug rezetecan

Start the discussion